Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × Vinorelbine × Dermatologic × Clear all
NCT00256282 2018-05-03

Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma

University of California, Irvine

Phase 2 Completed
52 enrolled 8 charts
Dermatologic

Melanoma

NCT00003828 2012-08-22

S9804: Vinorelbine in Treating Patients With Stage IV Melanoma

SWOG Cancer Research Network

Phase 2 Completed
24 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡